drugset / Trial / NCT04305548

Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma

NCT04305548

Phase 2 Recruiting 16 enrolled Italian Sarcoma Group PharmaMar · collab
NaSingle-groupOpen-labelTreatment

Summary

Prospective, uncontrolled, investigator-initiated, phase II clinical study to explore the activity of trabectedin in a population of patients aged ≥16 years with progressive, advanced (locally advanced or metastatic)

Timeline

Start
2021-09-14
Primary completion
2026-12-31
Completion
2026-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Trabectedin Small molecule 1.3 mg/m2
Subject Trabectedin Small molecule 1.5 mg/m2